Heart disease and risk of hospital admission for allopurinol-associated severe cutaneous adverse reactions, by demographic profiles
| Variable | (+) Heart disease | (−) Heart disease | ||
|---|---|---|---|---|
| Risk of hospital admission for allopurinol-associated severe cutaneous adverse reactions per 1000 patients (95% CI) | Multivariable relative risk* (95% CI) | Risk of hospital admission for allopurinol-associated severe cutaneous adverse reactions per 1000 patients (95% CI) | Multivariable relative risk* (95% CI) | |
| Female sex, region with high Asian population†; age, yr | ||||
| ≥70 | 3.65 (1.57–7.19) | 22.61 (7.57–67.60) | 3.12 (1.49–5.73) | 20.61 (7.69–57.46) |
| < 70 | 1.44 (0.17–5.21) | 9.13 (1.82–45.83) | 2.60 (1.35–4.55) | 17.52 (6.53–47.01) |
| Female sex, region with low Asian population†; age, yr | ||||
| ≥ 70 | 2.30 (1.05–4.37) | 13.76 (4.67–40.55) | 0.99 (0.43–1.95) | 6.42 (2.18–18.87) |
| < 70 | 1.63 (0.34–4.78) | 9.68 (2.35–39.80) | 0.67 (0.29–1.32) | 4.38 (1.51–12.73) |
| Male sex, region with high Asian population†; age, yr | ||||
| ≥ 70 | 2.72 (1.17–5.36) | 17.10 (5.78–50.55) | 2.77 (1.38–4.96) | 18.28 (6.73–49.68) |
| < 70 | 1.28 (0.42–2.99) | 8.43 (2.56–27.77) | 0.34 (0.12–0.73) | 2.33 (0.75–7.24) |
| Male sex, region with low Asian population†; age, yr | ||||
| ≥70 | 0.93 (0.34–2.03) | 5.48 (1.70–17.56) | 0.45 (0.15–1.05) | 2.92 (0.89–9.63) |
| < 70 | 0.36 (0.04–1.30) | 2.27 (0.45–11.34) | 0.14 (0.05–0.32) | 1.00 (Ref.) |
Note: CI = confidence interval, Ref. = reference category.
↵* Adjusted for chronic kidney disease, initial allopurinol dosage, diabetes, diuretics and gout.
↵† Proportion of Asian people in the population by region, according to data from the 2016 Canadian Census, is used here as a surrogate for Asian race, which has the highest prevalence of the HLA-B*5801 polymorphism.